Clinical effect of percutaneous coronary intervention in association with tirofiban hydrochloride in the therapy of acute myocardial infarction
Authors
- Jiangchuan Han * 1
- Guoliang Yuan 1
- Wei Li 2
- Tao Li 1
- Junming Chen 1
Abstract
Objective: To probe the influence of percutaneous coronary intervention (PCI) in association with tirofiban hydrochloride in the treatment of acute myocardial infarction (AMI).
Methods: A total of 116 AMI patients admitted to our hospital from January 2021 to December 2022 were chosen and separated into control group (CG, n=58) as well as study group (SG, n=58). Patients in the CG adopted PCI, and patients in the SG adopted tirofiban hydrochloride in association with PCI. The average hospital stay and bed time, clinical efficacy, TIMI flow grades, levels of cardiac function index and cardiac markers, along with occurrence of adverse reactions in both groups were compared.
Results: The average hospital stay together with bed time in the SG were lessened relative to the CG (P<0.05). The total effective rate of the SG was promoted relative to the CG (χ2=4.64, P<0.05). After treatment, the TIMI blood flow grade 3 in the SG was higher in comparison with the CG (P<0.05). EF levels were elevated and LVEDD and LVESD levels were declined in the SG in comparison with the CG (P<0.05). CK-MB and cTnI levels were reduced in the SG relative to the CG (P<0.05). The occurrence of adverse reactions in the SG was decreased compared to the CG (P<0.05).
Conclusion: Tirofiban hydrochloride combined with PCI is effective in patients with AMI, which can elevate the recovery of cardiac function, decrease the levels of CK-MB and cTnI, lessen the occurrence of cardiovascular adverse reactions, as well as has high safety.
